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ackground: Multiple documentary evidence comprising genome wide association studies have 
established association of TLR7 and TLR9 gene polymorphisms with systemic lupus erythematosus 
(SLE). Present study was aimed to deduce and compare single nucleotide polymorphism (SNP) in TLR7 
(rs179008) and TLR9 (rs352140) genes between local population of SLE patients and healthy controls. 
Methods: A case control study; blood samples from 80 controls (Group1) and 80 SLE subjects (Group2) were 
collected in EDTA tubes and processed for the analysis of gene polymorphism of TLR7 (rs179008) and TLR9 
(rs352140) by PCR-RFLP after DNA extraction. Complete blood counts were also determined. Statistical 
analysis was carried out using Chi-square test for SNPs analysis and allele frequencies between two groups. 
TLR 7 and TLR 9 genes polymorphism with SLE alongside clinical parameters were assessed.  
Results: Genotypes of TLR7, AT and TT are not significantly associated with SLE. Whereas, TLR9 CT and TT 
genotypes, especially T allele are significantly associated with SLE reflecting noticeable interdependence of 
TLR9 gene polymorphism with respect to SLE subjects.  
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Introduction  
Systemic lupus erythematosus (SLE) is an autoimmune 
disease where autoantibodies are produced against self-
nuclear and cytoplasmic constituents; specifically double 
stranded DNA (dsDNA). Autoantibodies react with self-
antigens and form immune complexes which get 
deposited in tissues resulting in inflamed organs such as 
kidneys, joints, central nervous system, etc [1]. 
Worldwide it is more prevalent in females than males 
with a ratio of 9:1 [2]. 
Several environmental factors e.g. particulates in air 
pollution, ultraviolet light, infection and cross reactivity of 
antibodies with self-antigens lead to development of SLE 
[3]. Inappropriate regulation of lymphocyte production 
leads to a state of immunological hyperactivity that 
further converts to SLE [4]. Clearance of immune 
complexes, APC (antigen presenting cell), B cells, T cells 
signal transduction and toll like receptors 
(TLRs)/interferon signaling pathways are three well 
established immunological pathways which account for 
the pathological process of SLE [3] [5,6].  
Range of ligands including proteins, lipids and nucleic 
acids derived from both micro-organisms and 
endogenous tissues are recognized by TLR. After 
interaction with specific ligands, TLRs signal via 
recruitment of specific adapter protein channels. Those 
adapter proteins interact with interleukin 1 receptor 
domain that initiates a series of other signaling pathways 
followed by transcription activation factors that trigger 
gene expression of pro-inflammatory chemokines and 
cytokines as well as interferon regulatory factors [7,8]. 
Hyper activation of these receptors has been attributed 
to the pathogenesis of autoimmune disorders [9]. Ten 
human (TLR1 to TLR10) and twelve murine TLRs (TLR1 
to TLR9, TLR11, TLR12 and TLR13) have been 
characterized [10]. Mice and human TLR7 and TLR9 are 
linked with autoimmune disorders e.g. SLE [11]. TLR7 
and TLR9 recognize ssRNA and nonmethylated 
cytosine–phosphate–guanine (CpG) dinucleotide motifs 
located in bacterial, viral and fungal DNA [12,13]. 
Defective interferon/TLR signaling pathways induce 
immune complexes comprising of self-nucleic acid to 
interact with TLR7 and TLR9 within plasmacytoid 
dendritic cells and B cell endosomes leading to the 
secretion of type 1 interferon and (IL)-6 [14]. The 
combined activation of both B cell receptor and TLR 
leads to the proliferation of auto-reactive B-cells. 
Subsequent differentiation into plasmablasts and plasma 
cells result in secretion of autoantibodies [15]. 
The findings of various studies on TLR polymorphism 
and SLE are inconsistent and up to the best of our 
knowledge, there was no study from Pakistan on TLR in 
account to SLE. Therefore, present study was designed 
to determine TLR 7 (rs179008) and TLR 9 (rs352140) 
polymorphisms in SLE patients. 
Methods 
It was a case control study that included age and gender 
matched 80 healthy individuals as controls (group 1) and 
80 SLE patients (group 2). The study was approved by 
the ethical review committee of Fatima memorial hospital 
Lahore and University of Health Sciences (UHS) Lahore. 
It was carried out in the department of immunology at 
UHS. After the informed consent samples were collected 
from the patients who appeared in rheumatology clinic of 
Fatima memorial hospital and controls were recruited 
from healthy population of UHS. Convenaient sampling 
technique was applied. 
Group I:  Apparently, healthy controls. 
Group II: SLE patients.  
Inclusion criteria : 
Control: 
Both male and female between 18-60 years of age. 
Healthy individuals. 
Patients: 
Both male and female between 18-60 years of age. 
Diagnosed SLE patients based on ACR diagnostic 
criteria. 
Exclusion criteria:   
Subject with recent history of infection in last two weeks. 
• Patients with autoimmune disease other than 
SLE 
• Other chronic conditions (Diabetes mellitus) 
• Malignancy 
Sample processing and genotyping  
DNA extraction from whole blood was carried out in the 
department of immunology UHS, Lahore. Complete 
blood counts were performed on sysmex XE-2100 
instrument while ESRs were estimated on vesmatic 
cube30 instrument. 
Extraction of DNA from whole blood was carried out 
using phenol and chloroform method [16]. Extracted 
DNA samples were stored at -20˚C until further 
processing. Polymorphism analysis of TLR7 (rs179008) 
and TLR9 (rs352140) was performed by polymerase 
chain reaction-restriction fragment length polymorphism 
(PCR-RFLP). Primer pairs for TLR7 and TLR9                       
F:5′ TAACAACGAATAGGAAAATGC 3′, R:5′ 
GTTTTAGGAAACCATCTAGCC 3′ and F: 5′-
GCAGCACCCTCAACTTCACC -3′, R: 5′-
GGCTGTGGATGTTGTTGTGG -3′ were used for PCR 
respectively. PCR-amplified fragments of TLR7 were 
comprised of 369 base pairs (bp) and TLR9 possessed 
360bp in length. Polymorphism analysis of TLR7 and 
TLR9 was conducted and genotype was assessed by 
restriction digestions of all the amplified DNA products 
with N1aIII and BstUI enzymes at 37ºC for 4 hours. 
Digested PCR products were electrophoresed on 1.5% 
TAE agarose gel for 40 minutes (90 volts) and visualized 
by ethidium bromide staining under UV. The digested 
product of TLR7 had 3 genotypes (AA), (AT), (TT) and 
similarly TLR9 had 3 genotypes (TT), (CC), (CT). TLR7 
A allele was cleaved into 243bp and 126bp fragments 
while TLR7 T allele remained uncut. TLR9 C allele was 
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Statistical analysis was performed using SPSS version 
20. Mean ± SD was given for quantitative variables such 
as age and hemoglobin. Using Chi-square test; 
polymorphisms were tested for deviation from Hardy–
Weinberg equilibrium by comparing the observed and 
expected genotype frequencies. For SNP analysis, 
genotype and allele frequencies of TLR7 and TLR9 were 
compared between groups by Chi-square test, odds 
ratios (OR) and confidence intervals (CIs) were 
calculated using logistic regression. A p-value ≤ 0.05 was 
considered as statistically significant. 
Results 
Subjects with SLE had mean (± SD) age of 30.72±7.77 
years almost similar to the controls 30.70±7.65 years. 
Comparatively, there was no statistically significant 
difference between two groups (p=0.984). Among SLE 
patients 73 (91.25%) were positive for ANA whereas, 76 
(95%) were positive for anti dsDNA antibodies: which is 
suggestive of diagnostic efficacy of anti dsDNA assay 
(Table 1). 
Variables Patients (n=80)  
dsDNA 76 (95%) 
ANA 73 (91.25%) 
n=number of patients, %=percentage  
Table 1: Percentages of dsDNA and ANA in SLE patients 
Levels of hemoglobin in group 1 (controls) and group 
2 (SLE patients) were 14.1 g/dl and 11.4g/dl respectively; 
statistically significant difference was detected 
(p<0.0001). The level of ESR was high in SLE patients 
(52.5 mm/hour) compared to controls (13.0 mm/hour) 
and there was statistically significant difference between 
the two groups (p<0.0001).  
Polymorphism of TLR7 and TLR9 in SLE patients: 
OR of TLR7 polymorphism for AT genotype was 1.093 
and for TT it was 0.928 and  no statistically  significant 
association was found  with respect to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
AT and TT genotypes with SLE (p=0.875 and TT=0.890 
respectively). There was no significant association of 
TLR7 polymorphism with SLE (Table 2). 
The OR of TLR9 polymorphism for CT genotype was 
3.139 (95% confidence interval, p= 0.004) and for TT 
genotype it was 3.825 (95% confidence interval, 
p=0.003) which indicates that individuals with CT 
genotype of TLR9 polymorphism are three times, and 
those with TT genotype are almost four times more prone 
to develop SLE. 
Association of T allele (TLR7 and TLR9) with SLE: 
There is no statistically significant association (p=0.75) 
and presence of T allele is not associated with the onset 
of SLE in TLR7 (OR of 1.156 and confidence interval 
0.6283-2.216). However the presence of T allele is 
positively associated (p=0.001) with the onset of SLE in 




















































Table 2: Distribution of TLR7 and TLR9 polymorphism in SLE 
patients 
T allele  
Disease (SLE) 























Exposure (T allele)        
No 





0.001 69 99 
Table 3: Association of TLR 7 and TLR9 with SLE 
TLR9 (rs352140) polymorphism with different clinical 
manifestations of SLE: 
Among patients with renal manifestation, frequency of 
CT and TT genotype was 23 and 13 respectively and it 
was associated with these genotypes but not significant 
(OR=1.862 [0.594-5.839]). Similarly, among patients 
with immunological manifestations, frequency of CT and 
TT genotype was 29 and 17 respectively and showed no 
association with these genotypes (OR=2.118 [0.653-
6.668]) (Table 4). 
Characteristic CC CT TT Odds ratio (95% CI)  
Malar rash 9 31 10 - 
Discoid rash 5 13 7 - 
Photosensitivity  6 21 9 - 
Oral or 
nasopharyngeal 
4 18 10 - 
Arthritis  4 9 6 - 
Serositis 3 7 4 - 
Renal  6 23 13 1.862 (0.594-5.839) 
Neurologic  7 15 9 - 
Hematologic  9 19 11 - 
Immunologic  8 29 17 2.118 (0.653-6.668) 
Table 4: Distribution of TLR9 (rs352140) polymorphism among 
SLE patients with different clinical manifestations 
Discussion 
In this study the relationship between two SNPs 
encoding genes i.e. TLR7 and TLR9 with occurrence of 
SLE was investigated. Mean (± SD) age of SLE subjects 
was 30.72 ± 7.77 which was in agreement with Rabbani 
et al, who reported mean age of 31 years [17]. Rubtsov 
et al, studied over expression of the genes mediating the 
formation of B Cells from partially non-ionized parts of 
the X chromosome known to contribute to the 
development of autoimmune condition in females [18].   
 In the present study ANA was detected in 91.25 % 
whether anti ds DNA antibodies were more frequent 
(95%) among diagnosed study subjects: which is 
suggestive of diagnostic efficacy of anti-ds DNA. 
Aforementioned study is in conformity with the study of 
Solangi et al, who documented 88.3% ANA in SLE 
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patients. They also stated 96.81 % of anti dsDNA 
antibodies in SLE patients which is also supportive to the 
present study [19].  
In the current study, hemoglobin in group I was 14.1 
g/dl which is in normal range. The level of hemoglobin 
was 11.4g/dl in group II. These finding are in accordance 
with Voulgarelis et al, who reported hemoglobin as 9 to 
11 g/dl [20]. Lam and Quah, deduced that low 
hemoglobin levels can be caused by impaired 
erythropoietin production by kidneys, loss of gastro-
intestinal blood due to anti-inflammatory therapy, 
increased red cell destruction from hypersplenism or a 
drug-induced immune phenomenon [21]. 
Frequency of TT in group II was 26 (32.5%) whereas 
in group I it was 16 (20%), OR (95% CI) =3.825 (1.586-
9.226), and p= 0.003. The frequency of CT in group II 
was 39 (48.8%) while in group I it was 29 (36.2%), OR 
(95%CI) =3.139 (1.448-6.805), and p=0.004. Increased 
OR was observed in SLE patients with TT compared to 
CC, which means that patients possessing T allele might 
be at risk for developing SLE. It supports Zhang et al, 
who reported TLR9 (rs351240) TT genotype, minor allele 
T and haplotype H3 increases susceptibility to SLE in 
northern Chinese population [22]. Xu et al, also 
documented that individuals with T allele at TLR9 
(rs352140) have increased risk of SLE [23]. Another 
study by Nakano et al, divulged that extent of TLR9 
mRNA in B cells was raised in SLE patients [24]. 
Piotrowski et al, showed that TLR9 (rs352140) 
polymorphism was not associated with SLE in Polish 
population [25]. Huang et al, showed polymorphism of 
TLR9 (rs187084) that is located in LD block with 
(rs352140) is associated with SLE in Taiwanese patients 
[26]. Similarly a study by Xu and Mu et al, revealed 
significant association of TLR9 (rs352140) with the 
susceptibility to SLE in Chinese population. They 
revealed high expression of TLR9 in SLE patients who 
had anti dsDNA antibody than patients who did not 
possess these antibodies [23,27]. A meta-analysis 
update by Lee et al, in Asian population projected 
association of TLR9 (rs352140) with SLE [28]. Elloumi et 
al, illustrated significant association of TLR9 (rs352140) 
with lupus nephritis patients [29].   
Zhou et al, did not find a significant contribution of the 
TLR9 (rs352140) polymorphism to SLE development in 
Chinese Han population [30]. Moreover, a meta-analysis 
study in African, Asian and Caucasian cohorts by Lee et 
al, reflected lack of association between TLR9 
(rs352140) alleles and SLE [31].  
Patients displaying T/T and T/C genotypes are at 
substantial risk of acquiring renal disease in SLE. The 
study is in agreement with Piotrowski et al, who also 
established the same results [25]. Zhou and Piotrowski 
et al, observed that patients having same genotypes are 
at risk of developing renal disease. They also suggested 
TLR9 T/T and T/C genotypes are significantly related 
with immunological disorders and presence of anti-
dsDNA antibodies in SLE patients [25,30]. Furthermore, 
Elloumi et al, illustrated significant association of TLR9 
(rs352140) genotypes with renal manifestation as 
congruent with our findings [29]. The conflicts and 
deviations in the impressions of TLR9 polymorphisms 
and development to SLE alongside clinical expressions 
in several populations may be due to multiracial 
heterogeneity and vulnerability of population to different 
environmental factors.  
Sanchez et al, Enevold et al, emphasized the role of 
TLR7 gene in the development of SLE. However, present 
study is in agreement with Sánchez et al, who conducted 
a case control study of 1107 healthy controls and 753 
SLE patients and observed no association of TLR7 
(rs179008) polymorphism with SLE in Spanish 
population [32,33]. Conversely, this study is not in 
agreement with Santos et al, who proved that T allele on 
the same loci remarkably raised the risk of SLE in 
Brazilian population [34]. That variation in result can be 
due to factors ranging genetic backgrounds, sample size 
and study designs. 
This study is significant in the way that the findings are 
in particular to our local Pakistani cohorts and it will open 
a gateway for further understanding of disease pattern 
and advancements within this particular domain. SNP in 
TLR9 gene (rs351240) is associated with SLE while SNP 
in TLR7 (rs179008) is not associated with SLE in 
Pakistani population. Those findings may incorporate in 
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